stoxline Quote Chart Rank Option Currency Glossary
  
CG Oncology, Inc. Common stock (CGON)
30.26  -0.06 (-0.2%)    02-06 10:13
Open: 30.41
High: 30.59
Volume: 91,169
  
Pre. Close: 30.32
Low: 30.18
Market Cap: 2,304(M)
Technical analysis
2025-02-06 9:46:07 AM
Short term     
Mid term     
Targets 6-month :  37.5 1-year :  43.8
Resists First :  32.11 Second :  37.5
Pivot price 30.07
Supports First :  29.38 Second :  27.7
MAs MA(5) :  29.97 MA(20) :  29.89
MA(100) :  33.55 MA(250) :  35.2
MACD MACD :  -0.1 Signal :  -0.2
%K %D K(14,3) :  65.8 D(3) :  62.4
RSI RSI(14): 50.2
52-week High :  50.22 Low :  25.77
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ CGON ] has closed below upper band by 43.6%. Bollinger Bands are 61.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 30.5 - 30.65 30.65 - 30.78
Low: 29.18 - 29.35 29.35 - 29.5
Close: 30.04 - 30.32 30.32 - 30.57
Company Description

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

Headline News

Tue, 17 Dec 2024
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - The Manila Times

Tue, 17 Dec 2024
Cg oncology director Leonard Post sells $28,840 in stock - Investing.com

Tue, 17 Dec 2024
Cg oncology director Song Hong Fang sells shares worth $19.6 million - Investing.com

Mon, 16 Dec 2024
CG Oncology Raises $238M in Successful Public Offering at $28 Per Share - StockTitan

Thu, 12 Dec 2024
CG Oncology Launches Major $204M IPO with Shares Priced at $28, Backed by Top Wall Street Banks - StockTitan

Wed, 11 Dec 2024
CG Oncology Launches Major 8M Share Public Offering, Backed by Top Wall Street Banks - StockTitan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 76 (M)
Held by Insiders 4.503e+007 (%)
Held by Institutions 6.2 (%)
Shares Short 4,990 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -9.594e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -65 %
Return on Assets (ttm) 802.3 %
Return on Equity (ttm) -15.7 %
Qtrly Rev. Growth 684000 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth -15.9 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -73 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 6.37e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android